Forschungszentrum Juelich Gmbh

Priavoid Gmbh

Heinrich-heine-universitaet

Forschungszentrum Julich Gmbh

Heinrich-heine-universität

Dieter Willbold

Susanne Aileen Funke

Luitgard Nagel-Steger

Dirk Bartnik

Oleksandr Brener

Janine Kutzsche

Oleksander Brener

Carsten Korth

Antonia Nicole Klein

Oliver Bannach

Hans-Ulrich Demuth

Martin Kleinschmidt

Andreas Müller-Schiffmann

Julian Glueck

Patricia Hidalgo Jimenez

Daniel Frenzel

Maren Huelsemann

Verian Bader

Stephan Rudolph

Antonia Klein

Steffen Huebinger

Lothar Gremer

Heiner Schaal

Gustavo Adolfo Guzman Castro

Marek Widera

Dagmar Juergens

Christian Zafiu

Yeliz Cinar

Hans-Henning Ludwig

Eva Birkmann

Kateryna Kravchenko

Silke Hoffmann

Andreas Mueller-Schiffmann

Andreas Kulawik

Aileen Funke

Steffen HÜBINGER

Lei Wang-Dietrich

Julian GLÜCK

Maren HÜLSEMANN

Tran Thi Tuyen Bujnicki

Susanne Mödder

Amine Aladag

Katja Wiesehan

Julian Glück

Thi Tuyen Tran

The invention relates to amyloid beta-binding peptides and the use thereof for the treatment and the diagnosis of Alzheimer's disease.

Amyloid-beta-binding peptides and the use thereof for the treatment and diagnosis of Alzheimer's disease

The present invention relates to a composition consisting of or containing peptides selected from the group consisting of or containing RD2, D3, homologs having at least 50% identity and derivatives of RD2 or D3 and also polymers containing or consisting of RD2/D3 homologs having at least 50% identity and derivatives of RD2 and under D3 for use as an analgesic, for use in pain therapy, for use in the treatment of chronic and/or neuropathic pain and/or for inhibiting N-type neuronal calcium channels (NCCs).

Methods of treating chronic and neuropathic pain mediated by N-type neuronal calcium channels using D-enantiomeric peptides

The invention concerns a method for detecting indicators for determining diseases (disease indicators), in which aggregates of misfolded proteins play a role, and a method for selective quantitation and/or characterization of these disease indicators.

Method for detecting indicators for determining diseases

Amyloid beta-binding peptides and the use thereof for the treatment and the diagnosis of Alzheimer's disease.

Amyloid-beta-binding peptides and the use thereof for the treatment and diagnosis of alzheimer's disease

An inorganic nanoparticle is provided (step A) having the size of the aggregate of the protein misfolding disease. Free amino groups or free carboxyl groups are formed (step B) on the surface of the nanoparticle (for functionalizing the nanoparticle surface into an amine- or carboxy-functionalized nanoparticle. Maleinimido spacer carboxylic acid is bound to the free amino groups in step (B). Or, free carboxyl groups in step (B) are converted into NHS esters. Monomers of the protein aggregate are bound i) to the maleinimido spacer carboxylic acids by way of a sulfhydryl group at the free end of the monomers, or ii) to the NHS esters by way of the amino group at the free end of the monomer. A standard is provided for use in the detection of protein aggregates occurring with protein misfolding diseases.

Method for producing a standard for detecting protein aggregates of a protein misfolding disease, standard and use thereof

The present invention relates to novel D-enantiomeric A-beta-oligomer-binding peptides, homologs, fragments, parts and polymers thereof and use thereof.

D-enantiomeric peptides derived from D3 and use thereof

The invention relates to the treatment of blood, blood products and organs for the removal and/or detoxification of amyloid-beta oligomers.

Method for treating blood, blood products and organs

A method for the quantitative characterization of substances with regard to their properties of binding to amyloid-&#x3b2; (A&#x3b2;) conformers, comprising the steps of: &#x2014;fractionating a sample including various A&#x3b2; conformers; &#x2014;immobilizing a biotinylated A&#x3b2; conformer of the desired fraction on the surface of a substrate having high affinity for biotin; and &#x2014;deriving the binding behavior of an aggregate quality control probe to the desired A&#x3b2; conformer from the measurement signal by determining the kinetic and/or thermodynamic parameters. A device for carrying out the method.

Method for quantitative characterization of substances with regard to their properties of binding to amyloid-&#x3b2; (A&#x3b2;) conformers

A peptide comprising at least one peptide binding to an amyloid beta species, wherein the peptide includes an amino acid sequence that is present in cyclized form. The use of the peptides in medicine, in particular for treating Alzheimer's disease, is disclosed.

Cyclic, amyloid beta-binding peptides and the use thereof

Peptides specifically binding amyloid beta and to methods of treating and diagnosing Alzheimer's dementia using such peptides are provided.

Specific amyloid beta binding peptides and the use of same for treating and diagnosing alzheimer's dementia

The invention relates to peptides binding specifically to Abeta species for treating and/or diagnosing Alzheimer's disease.

Specific A-beta species-binding peptides for the therapy and/or diagnosis of Alzheimer's dementia

A method for the quantitative characterization of amyloid and/or aggregated peptides and/or proteins in a sample, comprising:&#x2014;providing a sample, wherein the sample includes an amyloid and/or aggregated peptide and/or protein having at least one aggregate size and shape;&#x2014;adding an active ingredient to be analyzed to the sample solution;&#x2014;separating the amyloid and/or aggregated peptides and/or proteins are from one another according to their aggregate size and shape;&#x2014;optionally completely denaturing the amyloid and/or aggregated peptides and/or proteins of a particular fraction into monomer building blocks;&#x2014;determining the change in concentration of the peptide and/or protein building blocks in at least one fraction by comparison against control values without the active ingredient.

Method for the quantitative characterization of amyloid and/or aggregating peptides and/or proteins in a sample

An agent for preventing and/or treating HIV and other viral infections. The agent in particular comprises at least one peptide, including an amino acid sequence, which is suitable for preventing fibrils associated with Alzheimer's disease, and/or homologs, fractions and parts thereof, so as to treat and/or prevent HIV and/or other viral infections.

Agents for preventing and treating HIV and other viral infections

Growing community of inventors

Juelich, Germany

Dieter Willbold